CTMX Stock — CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (CTMX)

Updated October 16, 2026.

CTMX is a Stock. Total return is -82.3% over the past 11 years, 436.1 points behind SPY at 353.8%.

CytomX Therapeutics is an oncology-focused biopharmaceutical company developing targeted biologics using its conditional activation platform technology, with a pipeline that includes T-cell engaging bispecific antibodies, conditionally activated antibody-drug conjugates, and cytokine therapies in collaboration with major pharmaceutical partners including Bristol Myers Squibb, Regeneron, and Moderna. The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage oncology biotechnology development rather than current income.

CTMX performance versus SPY

Price and return data through 2026-10-16.

Total return is -82.3% over the past 11 years, 436.1 points behind SPY at 353.8%. Over the past year its total return — price change plus distributions reinvested — is -30.5%. Its deepest 1-year drawdown was 67.0%.

CTMX key facts

Asset type

Stock

Asset class

Equity

Inception date

10/08/2015

Distribution frequency

None

Last close

$2.28 (as of 2026-10-16)

Market cap

$496,810,368

Average volume

3178659.0

Beta

2.139

Payout ratio

0.0%

Forward P/E

14.2045

EPS

$-0.57

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CTMX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.0%.

Who may consider CTMX — and who may not

It is a weaker fit for investors who need monthly cash flow (CTMX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CTMX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions